Envoy Medical Achieves Major Milestone in Clinical Trial for Fully Implanted Cochlear Implant [TheStreet.com]
Envoy Medical, Inc. - Class A (COCH)
Company Research
Source: TheStreet.com
a significant achievement in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant. The first three patients, who were implanted at the start of 2025, have successfully completed their 12-month follow-up evaluations. This milestone marks a critical step forward in the study and keeps the company on schedule for its Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA). Brent Lucas, CEO of Envoy Medical, expressed his excitement about the progress, stating, “We are thrilled to see the first wave of trial participants reach and complete their 12-month endpoint. Our breakthrough technology has the potential to redefine how severe to profound hearing loss is treated and could significantly increase adoption rates. With the trial fully enrolled and 12-month data now being collected, the future of hearing implants is closer than ever.” The Acclaim® cochlear implant is a groundbreaking, fully implanted device designed to address severe
Show less
Read more
Impact Snapshot
Event Time:
COCH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COCH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COCH alerts
High impacting Envoy Medical, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
COCH
News
- Envoy Medical (COCH) was upgraded by Zacks Research to "hold".MarketBeat
- Envoy Medical (COCH) is now covered by HC Wainwright. They set a "buy" rating and a $2.50 price target on the stock.MarketBeat
- Small Cap Growth Virtual Investor Conference: Presentations Now Available for On-Demand ViewingGlobeNewswire
- Small Cap Growth Virtual Investor Conference Agenda Announced for February 5th [Yahoo! Finance]Yahoo! Finance
- Small Cap Growth Virtual Investor Conference Agenda Announced for February 5thGlobeNewswire
COCH
Sec Filings
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- 4/2/26 - Form DEF
- COCH's page on the SEC website